India’s Biocon, Advaxis In Pact To Develop Late-stage HPV Immunotherapy
This article was originally published in PharmAsia News
Executive Summary
The deal with Advaxis gives Biocon access to a novel HPV therapy for cervical cancer in India and other Asian markets with a high prevalence of HPV-associated cancers.